4 results
The systematic understanding of the effects of SGLT2i in the setting of HF will enable the design of rational physiology based strategies to decrease the burden of HF, which could have major clinical and research implications internationally.
To investigate whether 3 monthly Dmab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.
Does single subcutaneous injection with denosumab or placebo (NACL 0.9%) induces a shorter Total contact cast treatment duration and faster bonefracture healing (days) and does it prevent deformation of the foot in patients with Charcot foot
The primary objectives of this study are:• To determine the safety and tolerability of EP-104IAR• To determine the pharmacokinetic (PK) profile of EP-104IARA secondary/exploratory objective is:• To evaluate the efficacy of EP-104IAR on eosinophilic…